| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/14/2004 | US6790626 Comprises preference for pyrimidine nucleotides (uridine triphosphate) over purine nucleotides; for determining ligand binding, detecting expression, drug screening, treatment |
| 09/14/2004 | US6790615 Methods and compositions for regulating cell cycle progression |
| 09/14/2004 | US6790606 Extracellular matrix signaling molecules |
| 09/14/2004 | US6790464 Administering radix, medulla, rhizoma, cortex, olibanum, herba, fructus, folium, semen, poria, stigma, and/or phaseolus plant extract; anticarcinogenic, antitumor, and antimetabolic agents |
| 09/14/2004 | US6790447 Peptides for treatment of autoimmune diseases |
| 09/14/2004 | US6790446 Campylobacter vaccine |
| 09/14/2004 | US6790444 Chimeric antibody comprising human immunoglobin constant region and murine variable region |
| 09/14/2004 | US6790443 Administering to the subject a therapeutically effective amount of an agent which inhibits binding of advanced glycation endproducts to any receptor for advanced glycation endproducts |
| 09/14/2004 | US6790440 Administration of a reactive oxygen species (ros) inhibitor or scavenger (a histmine or its salt, ester, prodrug and agonist) and at least one monocyte maturation promoting agent (a cytokine) |
| 09/14/2004 | US6790439 Thrombopoietin compositions |
| 09/14/2004 | CA2130115C Prevention of retinal injury and degeneration by specific factors |
| 09/14/2004 | CA2073113C Conjugates |
| 09/11/2004 | CA2458288A1 Method and compound to reduce the incidence of diabetes in a subject with chronic heart failure |
| 09/10/2004 | WO2004077062A2 Method for selecting a candidate drug compound |
| 09/10/2004 | WO2004076668A1 Modified tert promoter with enhanced tumor-specificity and strength and recombinant vector comprising the same |
| 09/10/2004 | WO2004076667A1 Double-strand rna oligonucleotide having effect of inhibiting the expression of cyclin b gene |
| 09/10/2004 | WO2004076666A1 Gasdermin family |
| 09/10/2004 | WO2004076657A2 Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides |
| 09/10/2004 | WO2004076650A2 Angiopoietin and fragments, mutants, and analogs thereof and uses of the same |
| 09/10/2004 | WO2004076639A2 Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus |
| 09/10/2004 | WO2004076635A2 Therapeutic applications of thrombomodulin gene via viral and non-viral vectors |
| 09/10/2004 | WO2004076634A2 Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease |
| 09/10/2004 | WO2004076632A2 Methods of screening for trpm5 modulators |
| 09/10/2004 | WO2004076631A2 Biologically active native biomatrix composition |
| 09/10/2004 | WO2004076626A2 Methods of gene therapy for treating disorders of the ear by administering a vector encoding an atonal-associated factor |
| 09/10/2004 | WO2004076619A2 New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
| 09/10/2004 | WO2004076484A1 Peptide inhibitors of thrombin as potent anticoagulants |
| 09/10/2004 | WO2004076483A1 Transcriptional factor inducing apoptosis in cancer cell |
| 09/10/2004 | WO2004076482A1 Soluble factor secreted by endothelial cells in blood vessels |
| 09/10/2004 | WO2004076480A1 Tumour marker and its use |
| 09/10/2004 | WO2004076479A2 Soluble ctla4 polypeptides and methods for making the same |
| 09/10/2004 | WO2004076478A1 PEPTIDE DERIVATIVES HAVING β-SECRETASE INHIBITORY ACTIVITY |
| 09/10/2004 | WO2004076476A1 Glycopeptide and use thereof as proteoglycan initiator |
| 09/10/2004 | WO2004076474A2 Polyethylene glycol modified interferon compositions and methods of use thereof |
| 09/10/2004 | WO2004076473A2 Androgen receptor interacting peptides |
| 09/10/2004 | WO2004075919A2 Compounds for protein stabilization and methods for their use |
| 09/10/2004 | WO2004075918A1 Liquid formulations of tumor necrosis factor-binding proteins |
| 09/10/2004 | WO2004075914A1 Methods for promoting wound healing and/or reducing scar formation |
| 09/10/2004 | WO2004075912A1 Use of pgrp, lrrp and ctl proteins to trigger an anti-plasmodium immune response in anopheles species |
| 09/10/2004 | WO2004075911A1 Chemokine binding protein and use thereof |
| 09/10/2004 | WO2004075910A1 Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis |
| 09/10/2004 | WO2004075909A1 USE OF THIOESTER-CONTAINING PROTEINS (TEPs) FOR TRIGGERING/INDUCING AN IMMUNE RESPONSE IN MOSQUITOES OF ANOPHELES AGAINST PLASMODIUM |
| 09/10/2004 | WO2004075908A1 Therapeutics for muscular dystrophy and therapeutic foods therefor |
| 09/10/2004 | WO2004075903A1 Combined use of ribavirin and interferon beta in demyelinating diseases |
| 09/10/2004 | WO2004075901A2 Compositon for increasing levels of hormones and a method for preparation of said composition |
| 09/10/2004 | WO2004075880A1 Particle formulation and its preparation |
| 09/10/2004 | WO2004075845A2 Methods for treating or preventing autoimmune disease using histamine h1 receptor-blocking agents |
| 09/10/2004 | WO2004075843A2 Glycosolated enkephalin agents |
| 09/10/2004 | WO2004075842A2 Mrp3 genes and uses thereof |
| 09/10/2004 | WO2004075838A2 Method and compositions for the treatment of meconium aspiration syndrome |
| 09/10/2004 | WO2004075837A2 Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| 09/10/2004 | WO2004075813A2 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep3 ii (prostaglandin e2 ep3 ii) |
| 09/10/2004 | WO2004075783A2 A method for stabilizing blood pressure in hemodialysis subjects |
| 09/10/2004 | WO2004075723A2 Methods for the early diagnosis of ovarian cancer |
| 09/10/2004 | WO2004075720A2 Use of intraputaminal infused glial cell-line derived neurotrophic factor in the treatment of parkinson’s disease in humans |
| 09/10/2004 | WO2004075636A1 Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease |
| 09/10/2004 | WO2004062685A3 Modification of feeding behaviour and weight control by oxyntomodulin |
| 09/10/2004 | WO2004058799A3 Methods and compositions for inhibiting binding of ige to a high affinity receptor |
| 09/10/2004 | WO2004052390B1 Methods and compositions for treating polycystic ovary syndrome |
| 09/10/2004 | WO2004052281A3 Oral lactoferrin in the treatment of sepsis |
| 09/10/2004 | WO2004050101A3 Formulations useful against hepatitis c virus infections |
| 09/10/2004 | WO2004043357A3 Method of making, and the use of cytotoxic agents containing elemental selenium |
| 09/10/2004 | WO2004042075A3 Inactivated ga1 - nac - transferases, methods for inhibitors of such transferases and their use |
| 09/10/2004 | WO2004039841A3 Trimeric binding proteins for trimeric cytokines |
| 09/10/2004 | WO2004039829A3 Use of cpg oligonucleotides in the treatment of hepatitis c virus infection |
| 09/10/2004 | WO2004039409A3 Composition comprising activators of ik potassium channels and calcineurin antagonists and use thereof |
| 09/10/2004 | WO2004037278A3 Delocalization molecules and use thereof |
| 09/10/2004 | WO2004037208A3 Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| 09/10/2004 | WO2004035624A3 Glucagon - like peptide - 2 variants |
| 09/10/2004 | WO2004029287A3 Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer |
| 09/10/2004 | WO2004019886A3 Methods for up-regulating antigen expression in tumors |
| 09/10/2004 | WO2004017044A3 Chimeric protein |
| 09/10/2004 | WO2004009759A3 Novel proteins in enteroaggregative escherichia coli (eaec) useful for diagnosis and therapy of eaec infections |
| 09/10/2004 | WO2004009027A3 Method and composition for treating and preventing herpesvirus infection |
| 09/10/2004 | WO2003106970A3 P27 prevents cellular migration |
| 09/10/2004 | WO2003101281A3 Method for reducing obstructive hydrocephalus |
| 09/10/2004 | WO2003099842A3 Compositions and methods of use for a bombesin peptide |
| 09/10/2004 | WO2003094844A3 Prostate cancer-related compositions, methods, and kits based on dna macroarray proteomics platforms |
| 09/10/2004 | WO2003093300A3 Anti-microbial peptides and compositions |
| 09/10/2004 | WO2003092594A3 Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use |
| 09/10/2004 | WO2003087092A3 Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease |
| 09/10/2004 | WO2003080807A8 Compositions and methods for suppressing eukaryotic gene expression |
| 09/10/2004 | WO2003076579A3 Cancer-linked gene as target for chemotherapy |
| 09/10/2004 | WO2003070897A3 RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 09/10/2004 | WO2003068967A3 Novel retina specific human proteins wdr17, net01, protein kinase a203, protein kinase mak a194, protein a105, protein a106 and c12orf3variants |
| 09/10/2004 | WO2003041655A3 Therapeutic agent composition and method of use |
| 09/10/2004 | WO2003016330A3 Molecular linkers suitable for crystallization and structural analysis of molecules of interest, method of using same, and methods of purifying g protein-coupled receptors |
| 09/10/2004 | WO2003006680A3 Omi and domains thereof that disrupt iap-caspase interaction |
| 09/10/2004 | WO2003003979A3 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 09/10/2004 | WO2002094780A3 Kinases and phosphatases |
| 09/10/2004 | WO2002064085A3 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
| 09/10/2004 | CA2519193A1 Methods for the early diagnosis of ovarian cancer |
| 09/10/2004 | CA2517834A1 Method for selecting a candidate drug compound |
| 09/10/2004 | CA2517285A1 Transcriptional factor inducing apoptosis in cancer cell |
| 09/10/2004 | CA2516857A1 Use of intraputaminal infused glial cell-line derived neurotrophic factor in the treatment of parkinson's disease in humans |
| 09/10/2004 | CA2516834A1 Polypeptides and methods for making the same |
| 09/10/2004 | CA2516651A1 Methods of screening for trpm5 modulators |
| 09/10/2004 | CA2516552A1 Polyethylene glycol modified interferon compositions and methods of use thereof |
| 09/10/2004 | CA2515975A1 Peptide derivatives having .beta.-secretase inhibitory activity |
| 09/10/2004 | CA2515916A1 Therapeutic applications of thrombomodulin gene via viral and non-viral vectors |